Soo koob maqaalka:  Shirkad soo saarta dawooyinka ayaa lagu eedeeyay inay isku dayday inay joojiso tijaabooyinka lagu doonayo in lagu horumariyo daaweynta "raqiis ah, amaan ah oo wax ku ool ah" ee aragga oo ku dhaca NHS. Waxay "ku cabsi gelisay" khubaro isku dayay inay caddeeyaan in daawada kansarka loo isticmaali karo in lagu daaweeyo mid ka mid ah noocyada ugu badan ee indho la'aanta, sida lagu sheegay BMJ. Joornaalka caafimaadka ee la ixtiraamo ayaa sheegaya in Avastin uu wax ku ool u yahay la tacaalida da'da da'da la xiriirta da'da da'da (AMD) sida daaweynta hadda jirta, Lucentis. Shirkadda dawooyinka ee Novartis ayaa lagu eedeeyay inay isku dayday inay joojiso tijaabooyin la doonayo in lagu horumariyo daaweyn "raqiis ah, ammaan ah oo wax ku ool ah" oo indho la'aan ah taas oo badbaadin lahayd NHS qiyaastii £102million sanadkii. Avastin waa mid aad u jaban, waxaana la qiyaasaa in isticmaalka baahsan ee daawada ay NHS-ta badbaadin doonto £102 milyan sanadkii. Laakiin BMJ waxay sheegtay in shirkadda dawooyinka ay si joogto ah isku dayday inay <unk> wiiqdo oo ay u weeciso dareenka <unk> tijaabooyinka si loo caddeeyo shaqada Avastin <unk> xitaa u jeestay Royal National Institute of Blind People (RNIB) caawimaad. Cudurka AMD waa nooca ugu badan ee aragga ee ku dhaca dadka da'doodu ka weyn tahay 50 sano. Natiijooyinka tijaabooyinka caafimaadku waxay muujinayaan in Avastin uu yahay mid amaan ah oo waxtar u leh daaweynta AMD <unk> laakiin waxay ku kacaysaa £ 70 daaweyn kasta marka la barbar dhigo £ 740 oo loogu talagalay duritaanka Lucentis. Novartis, oo Lucentis ku iibisa UK, ayaa la sheegay inay isku dayday inay "wax walba" ay awoodo si ay u joojiso tijaabooyinka daawada kansarka. BMJ waxay heshay emayl ku saabsan codsi xorriyadda macluumaadka oo muujinaya in dhakhaatiirta caafimaad ee xiriir la leh Novartis ay ku boorriyeen qaar ka mid ah kalsoonida daryeelka aasaasiga ah inay ka baxaan hal tijaabo Avastin ah, halka dadaallo la sameeyay si loo "dhaafsado" tijaabo labaad oo si dadban loo maalgeliyo UK. Madaxa baaritaanka Alex Foss oo ah dhakhtarka indhaha ee xarunta caafimaadka ee Queen's, Nottingham, ayaa u sheegay BMJ sida, inta lagu gudajiray marxaladda qorshaynta, wakiil ka tirsan Novartis uu isku dayay inuu u weeciyo shaqada Novartis ee maalgelinta <unk> iyadoo rajada laga qabo maalgelinta mustaqbalka ee mashaariicda cilmi baarista shaqsiyeed. BMJ ayaa sheegtay in shirkadda dawooyinka ee Novartis (sawirka) ay si joogto ah isku dayday inay "hoos u dhigto oo ay u weeciso dareenka" tijaabooyinka si ay u caddeeyaan in Avastin uu shaqeynayo xitaa u jeestay Royal...
Shirkadda dawooyinka ayaa lagu eedeeyay inay isku dayday inay joojiso tijaabooyinka lagu doonayo in lagu horumariyo daaweynta 'qiimaha jaban, aaminka ah iyo wax ku oolka ah' ee indho la'aanta NHS. Waxay ku cadaadisay khubaro isku dayay in ay caddeeyaan in daroogada loo isticmaali karo in lagu daaweeyo indho la 'aanta. Avastin wuxuu wax ku ool u yahay daaweynta xanuunka da 'da ee loo yaqaano " wet age-related macular degeneration " Waxay ka jaban tahay daaweynta hada jirta waxay badbaadin kartaa NHS £ 102 milyan sanadkii.